iifl-logo-icon 1

Ajanta Pharma Ltd Share Price

3,198.5
(2.48%)
Sep 19, 2024|03:32:07 PM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Equities

Futures

Option

  • Open3,134
  • Day's High3,225.35
  • 52 Wk High3,485
  • Prev. Close3,121.15
  • Day's Low3,123.6
  • 52 Wk Low 1,650.05
  • Turnover (lac)4,497.34
  • P/E46.93
  • Face Value2
  • Book Value292.15
  • EPS66.55
  • Mkt. Cap (Cr.)39,953.13
  • Div. Yield1.65
View All Historical Data
No Records Found

Ajanta Pharma Ltd KEY RATIOS

Sector

Pharmaceuticals

Open

3,134

Prev. Close

3,121.15

Turnover(Lac.)

4,497.34

Day's High

3,225.35

Day's Low

3,123.6

52 Week's High

3,485

52 Week's Low

1,650.05

Book Value

292.15

Face Value

2

Mkt Cap (₹ Cr.)

39,953.13

P/E

46.93

EPS

66.55

Divi. Yield

1.65

Ajanta Pharma Ltd Corporate Action

31 Jan 2024

12:00 AM

Dividend

Dividend Amount: 26

Record Date: 08 Feb, 2024

arrow

17 Jul 2024

12:00 AM

Board Meeting

Agenda : Audited Result

arrow

14 Jun 2024

12:00 AM

AGM

Announcement Date: 14 Jun, 2024

arrow

Ajanta Pharma Ltd NEWS AND UPDATE

No Record Found

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Ajanta Pharma Ltd SHAREHOLDING SNAPSHOT

19 Sep, 2024|08:48 PM
  • Foreign Promoter
  • Indian Promoter
  • Institutions
  • Non Institutions
  • Custodies

Promoter- 66.27%

Foreign: 0.00%

Indian: 66.27%

Non-Promoter- 25.79%

Institutions: 25.78%

Non-Institutions: 7.94%

Custodian: 0.00%

Share Price

Ajanta Pharma Ltd FINANCIALS

Balance Sheet

Profit & Loss

Cash Flow

Ratios

Results

Loading...
Y/e 31 Mar( In .Cr)Mar-2024Mar-2023Mar-2022Mar-2021

Equity Capital

25.27

25.27

17.17

17.39

Preference Capital

0

0

0

0

Reserves

3,388.3

3,221.18

3,152.01

2,867.59

Net Worth

3,413.57

3,246.45

3,169.18

2,884.98

Minority Interest

View Balance Sheet
Loading...
Y/e 31 Mar( In .Cr)Mar-2022Mar-2021Mar-2020Mar-2018

Revenue

3,140.64

2,718.59

2,196.42

1,825.35

yoy growth (%)

15.52

23.77

20.32

1.16

Raw materials

-832.56

-730.08

-663.97

-399.29

As % of sales

26.5

26.85

30.22

21.87

Employee costs

-585.87

-498.11

-437.82

-342.89

View Profit & Loss
Loading...
Y/e 31 Mar( In .Cr)Mar-2022Mar-2021Mar-2020Mar-2018

Profit before tax

900.54

902.09

616.59

562.44

Depreciation

-120.96

-111.49

-91.29

-57.14

Tax paid

-180.68

-226.45

-171.54

-134.92

Working capital

278.87

306.22

272.08

231.17

Other operating items

View Cash Flow
Loading...
Y/e 31 MarMar-2022Mar-2021Mar-2020Mar-2018

Growth matrix (%)

Revenue growth

15.52

23.77

20.32

1.16

Op profit growth

-2.83

72.09

-2.56

-13.8

EBIT growth

0.07

45.27

11.19

-12.34

Net profit growth

6.54

53.16

3.18

-14.46

View Ratios
Particulars (Rupees in Crores.)Mar-2024Mar-2023Mar-2022Mar-2021Mar-2020

Gross Sales

4,208.71

3,742.64

3,340.99

2,889.69

2,587.87

Excise Duty

0

0

0

0

0

Net Sales

4,208.71

3,742.64

3,340.99

2,889.69

2,587.87

Other Operating Income

0

0

0

0

0

Other Income

84.6

98.64

115.68

25.98

92.19

Ajanta Pharma Ltd Peer Comparison

Company Name
LTP
(₹)
P/E
(%)
Mkt.Cap
(₹Cr.)
NP Qtr
(₹Cr.)
Div.Yield
(%)
Sales Qtr
(₹.Cr)
Book Value
(₹)

Sun Pharmaceuticals Industries Ltd

SUNPHARMA

1,846.05

157.994,39,714.12237.820.744,409.7498.75

Divis Laboratories Ltd

DIVISLAB

5,429.2

87.391,45,166.184300.552,063507.93

Cipla Ltd

CIPLA

1,637.7

33.591,33,401.991,055.940.793,752.25346.39

Torrent Pharmaceuticals Ltd

TORNTPHARM

3,351.9

75.671,13,724.414690.832,394201.77

Dr Reddys Laboratories Ltd

DRREDDY

6,502.55

26.61,09,604.311,417.20.615,823.91,458.61

Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.

MORE ABOUT Ajanta Pharma Ltd

Management

Register Office

Registrar Office

Chairman (Non-Executive)

Mannalal B Agrawal

Vice Chairman

Madhusudan B Agrawal

Managing Director

Yogesh Agrawal

Independent Director

Chandrakanth M Khetan

Vice President & CS

Gaurang Shah

Joint Managing Director

Rajesh M Agrawal

Independent Director

K H Viswanathan

Independent Director

Prabhakar Dalal

Independent Director

Anjana Grewal

Independent Director

David Rasquinha

Independent Director

Medha Joshi

Independent Director

Simi Thapar

Independent Director

Rajesh Shashikant Dalal

Registered Office


Tel: -

Website: -

Email: -

Registrar Office


Tel: -

Website: -

Email: -

Summary

Ajanta Pharma is a specialty pharmaceutical formulation company primarily with a well-diversified Branded Generics business spread across India, the Rest of Asia, and Africa. The Company is involved in development, manufacturing and marketing of marketing of quality finished dosages in domestic and international markets. It produces a comprehensive range of specialty products targeting different therapeutic segments. It has strong chronic-focused product portfolio led by a first-to-market strategy and front-end presence which helps it outgrow the market. The companys business includes Branded Generics in emerging markets of Asia and Africa, Generics in the developed markets of USA and Institution sales. The branded generics business is spread in India and more than 30 emerging countries across Africa, CIS, the Middle East and South East Asia. In India, the Company has presence in high growth specialty segments of cardiology, dermatology, ophthalmology and pain management.In branded generic business in emerging markets in Asia and Africa, Ajanta Pharmas products cater to therapeutic segments like Anti-Biotic, Anti-Malarial, Anti-Diabetic, Cardiology, Gynecology, Orthopedics, Pediatric, Respiratory & General Health products. The companys institutional business comprises of supplies to various government bodies in India and supply of Anti-Malarial products under WHO approved programs in Africa.Ajanta Pharma operates 7 state-of-the-art manufacturing facilities in India and Maurit
Read More

Company FAQs

What is the Ajanta Pharma Ltd share price today?

The Ajanta Pharma Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹3198.5 today.

What is the Market Cap of Ajanta Pharma Ltd?

Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Ajanta Pharma Ltd is ₹39953.13 Cr. as of 19 Sep ‘24

What is the PE and PB ratio of Ajanta Pharma Ltd?

The PE and PB ratios of Ajanta Pharma Ltd is 46.93 and 11.43 as of 19 Sep ‘24

What is the 52 Week High and Low of Ajanta Pharma Ltd?

The 52-week high/low is the highest and lowest price at which a Ajanta Pharma Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Ajanta Pharma Ltd is ₹1650.05 and ₹3485 as of 19 Sep ‘24

What is the CAGR of Ajanta Pharma Ltd?

Ajanta Pharma Ltd's CAGR for 5 Years at 34.59%, 3 Years at 28.24%, 1 Year at 87.23%, 6 Month at 46.92%, 3 Month at 29.36% and 1 Month at 6.41%.

What is the shareholding pattern of Ajanta Pharma Ltd?

The shareholding pattern of Ajanta Pharma Ltd is as follows:
Promoters - 66.27 %
Institutions - 25.79 %
Public - 7.94 %

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Center

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020
  • Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge.
  • Pay 20% upfront margin of the transaction value to trade in cash market segment.
  • Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard.
  • Check your Securities / MF / Bonds in the consolidated account statement issued by NSDL/CDSL every month.
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp